Oaktree Acquisition Corp. III Life Sciences filed its quarterly report on Form 10-Q with the SEC on August 12, 2026, covering the quarter ended June 30, 2026, and reporting net income of $1,604,621 for the three-month period.

Key Highlights

  • Net income (Q2 2026): The company reported net income of $1,604,621 for the three months ended June 30, 2026, compared to $1,874,343 for the same period in 2025.
  • Trust Account balance: Cash held in the Trust Account stood at $205,280,770 as of June 30, 2026, up from $201,563,532 as of December 31, 2025.
  • Redemption value per share: Class A ordinary shares subject to possible redemption were carried at $10.69 per share as of June 30, 2026, compared to $10.50 per share as of December 31, 2025.
  • Shareholders' deficit: Total shareholders' deficit was $(7,488,653) as of June 30, 2026, compared to $(6,770,157) as of December 31, 2025.
  • Shares outstanding: As of August 12, 2026, there were 19,783,010 Class A ordinary shares and 4,799,758 Class B ordinary shares issued and outstanding.
  • General and administrative expenses: G&A expenses were $261,958 for Q2 2026 and $718,496 for the six months ended June 30, 2026.

Financial Results and Trust Account Activity for Q2 2026

According to the filing, Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) reported net income of $1,604,621 for the three months ended June 30, 2026, driven primarily by interest earned on cash held in its Trust Account of $1,866,579, which more than offset a loss from operations of $(261,958). For the six months ended June 30, 2026, net income totaled $2,998,742, compared to $3,533,134 for the same period in 2025, with Trust Account interest of $3,717,238 for the half-year period.

The condensed balance sheet disclosed total assets of $206,540,698 as of June 30, 2026, with the Trust Account representing the dominant component at $205,280,770. Total liabilities were $8,748,581, including a deferred underwriting fee payable of $6,719,660 and amounts due to a related party of $935,857. The company's accumulated deficit widened to $(7,489,191) from $(6,770,695) at December 31, 2025, reflecting accretion on Class A ordinary shares subject to possible redemption of $1,866,579 in Q2 2026 and $1,850,659 in Q1 2026.

The filing reported that 19,199,029 Class A ordinary shares remained subject to possible redemption as of June 30, 2026. The company disclosed net cash used in operating activities of $(255,295) for the six months ended June 30, 2026. Basic and diluted net income per share for both redeemable Class A and non-redeemable Class A and Class B ordinary shares was $0.07 for Q2 2026 and $0.12 for the first half of 2026. The registrant identified itself as a shell company, a smaller reporting company, and an emerging growth company.

What Was Disclosed

The 10-Q filing covers Oaktree Acquisition Corp. III Life Sciences' financial position and results for the quarter and six months ended June 30, 2026, including Trust Account balances, per-share redemption values, operating expenses, and shareholders' deficit as of that date.